Network Point-of-Care Glucose Testing Market Size, Share & Trends Analysis Report By Product (i-STAT, Accu-Chek Inform II, StatStrip, HemoCue, CareSens Expert Plus, BAROzen H Expert Plus), By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global network point-of-care glucose testing market size was valued at USD 1.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.9% from 2021 to 2028. High demand for remote patient monitoring, data-based patient analysis, and integration with advanced data transfer techniques are some of the key factors fueling the market growth. A large number of countries in Asia Pacific and the Middle East are showing a steep rise in the diabetes population. For instance, as per the International Diabetes Federation, in 2017, 72,946,400 cases of diabetes were diagnosed in India. Large growth opportunities in fast-growing economies and growing awareness of diabetes in these regions are anticipated to boost the demand for diabetes devices.

Network-based point-of-care glucose monitoring systems proved to be an effective tool in the diagnosis and monitoring of COVID-19 patients, especially in makeshift hospitals. Glucose monitoring in COVID-19 patients is important as diabetic patients are prone to various complications. Major hospitals use continuous glucose monitors that can provide real-time glucose reading and can be accessed from outside the isolation areas. Large data gathered in the process helps healthcare services providers in customizing the treatment regime for each patient. Integration with telemedicine and usage expansion in-home healthcare settings are the factors expected to fuel the market growth during the forecast period.

The rising prevalence of diabetes mellitus is critical as it is the root cause for several disorders, such as stroke, kidney failure, and cardiac disease, which are also considered to be comorbidities. Furthermore, diabetes condition is allied with the poor projection of COVID-19 and hence its management for patients with both COVID-19 and diabetes has gained attention. The POCT is driving the market owing to its several benefits such as ease of use, no need for trained professionals, lower price, and rapid turnaround time. Major market players are involved in the designing and development of blood glucose monitoring devices.

Several initiatives by governments and nonprofit organizations to increase diabetes awareness are expected to boost the adoption of advanced glucose meters. For instance, the Ministry of Health and Family Welfare and the WHO Country Office for India as well as other partners have launched a mobile health initiative known as mDiabetes. This health initiative is focused on increasing awareness about the early diagnosis and treatment of diabetes. Similarly, the WHO and the IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide. For instance, the WHO Diabetes Program is aimed at preventing type 2 diabetes, reducing complications, and improving the quality of life for people with diabetes.

Product Insights

The Accu-Chek Inform II held the largest revenue share of over 45.0% in 2020. The Accu-Chek Inform II glucose meter is designed for in-vitro diagnostic applications aiding in the determination of blood glucose levels. This glucose meter monitors blood glucose levels in capillary, venous, neonatal and arterial, and whole blood samples. Healthcare professionals adopt Accu-Chek Inform II as it serves as a bedside system that aids in the measurement of glucose and automates the management of data generated by blood glucose tests.

i-STAT is expected to expand at a CAGR of 4.2% over the forecast period. i-STAT portable clinical analyzer developed by Abbott is one of the POC analyzers used at patients’ bedside for critical care tests for electrolytes, coagulation, blood gases, and metabolites. The device is equipped with a number of testing cartridges for monitoring different sets of analytes, which eliminates the need for several analyzers for different analytes.

Regional Insights

North America dominated the market in 2020 with a revenue share of over 35.0%. The presence of key market players such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC is one of the major factors contributing to the regional market growth. This has increased the availability of glucose testing products, thereby contributing to revenue generation. In addition, favorable reimbursement policies aid in the rapid adoption of advanced products.

Europe is expected to expand at a lucrative growth rate during the forecast period. Faster CE approvals and universal healthcare systems are expected to boost the adoption of point-of-care glucose testing devices. The growth can be attributed to various factors such as the rising burden of diabetes, the increasing demand for rapid diagnostic tools for diabetes management, and the presence of local players, which have diverse product portfolios for POC diagnostics. For instance, HemoCue AB is a POC diagnostics company, situated in Sweden, offering POC testing solutions for better management of diabetes.

Key Companies & Market Share Insights

The market is currently dominated by a few major players. Increasing demand and technological advancements are expected to attract new entrants in upcoming years. The integration of advanced data transfer technologies, including BLE and Infrared, is anticipated to aid in new product launches. Existing products are continuously redesigned by the players to stay in the competition. The integration of telemedicine is expected to boost the demand for global as well as local brands in developing countries. Some prominent players in the global network point-of-care glucose testing market include:

• F. Hoffmann-La Roche Ltd.

•  Abbott

• Nova Biomedical

• Bayer AG/Ascensia diabetes care holdings AG

• Danaher

Network Point-of-Care Glucose Testing Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global network point-of-care glucose testing market report on the basis of product and region:

• Product Outlook (Revenue, USD Million, 2016 - 2028)

  • i-STAT

  • Accu-Chek Inform II

  • StatStrip

  • HemoCue

  • CareSens Expert Plus

  • BAROzen H Expert Plus

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE